🧫
Preinjury ACE-I/ARB exposure and outcomes in transfused trauma patients
active
experiment
Created: 2026-04-10T22:45:09
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-ce218d4c-2968-43a6-b813-a80390f06721
🧫 Experiment Protocol
Clinicaltraumahuman patientsproposed
This retrospective clinical study evaluated the association between preinjury angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) medication use and clinical outcomes in trauma patients who received blood product transfusions during resuscitation. The study compared patients who had been taking ACE-I/ARB medications prior to their injury with those who had not been taking these medications. The researchers examined demographics, complication rates, blood product transfusion volumes, and mortality outcomes. The study aimed to determine if preinjury use of renin-angiotensin-aldosterone system modulators affected patient outcomes following traumatic injury requiring blood transfusion. Both univariate and multivariable analyses were performed to identify independent predictors of mortality, with adjustment for potential confounding variables including age, mechanism of injury, vital signs, laboratory values, and injury severity.
PRIMARY OUTCOME
24-hour mortality rate
EXPECTED OUTCOMES
Based on previous sepsis research showing improved mortality with ACE-I/ARB use, researchers expected potential mortality benefit in trauma patients with preinjury ACE-I/ARB exposure
SUCCESS CRITERIA
Statistically significant difference in mortality rates between ACE-I/ARB exposed and non-exposed groups, with significance maintained after multivariable adjustment
PROTOCOL
Retrospective analysis comparing trauma patients receiving blood transfusions who had preinjury ACE-I/ARB exposure versus those without such exposure. Demographics, complications, transfusion volumes, and mortality were evaluated using univariate and multivariable logistic regression analyses.
Source: PMID 41936145 ↗
🧫 Experiment Extras
PATHWAY
renin-angiotensin-aldosterone system
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.